March 21st 2021
By Tony Hagen
Biosimilars are intended to save money for the health care system, but for many reasons, they are not succeeding in this mission, Harvard authors argue.
March 17th 2021
State Senator Carla Nelson explains how the pharmaceutical industry is reacting to her bill requiring payers to cover all approved biosimilars and reference products.
Coverage policies for biosimilars in the health care industry are the source of much angst.
March 16th 2021
"Shocked" by the threat of competition, originator manufacturers start raising prices long before rival products appear on the scene, investigators found.
March 14th 2021
State Representative Jennifer Schultz (D, Duluth) explains how her bill requiring payers to cover all approved biosimilars and reference products would save money and improve access.
March 13th 2021
The Senate has passed a bill requiring the FDA to provide educational information that supports and promotes the adoption of biosimilars.
March 11th 2021
By Deana Ferreri, PhD
Unsustainably low prices for generics are preventing some manufacturers from producing them, while biosimilars are blocked by policies that favor originator drugs, the Association for Accessible Medicines (AAM) argues.
March 9th 2021
Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of Biosimilars at Cardinal Health, discusses motivating factors that affect use of biosimilars in oncology.
March 6th 2021
Minnesota legislators introduce what could possibly become the first law to curtail payers' rights to determine which biologics patients have access to.
March 1st 2021
The National Comprehensive Cancer Network (NCCN) recommended providers contact their legislators to counteract single-biosimilar payer policies.
